NXP900 Clinical Trials
2 recruitingDrug
Phase 12
Showing 1–2 of 2 trials
Recruiting
Phase 1
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Advanced Solid TumorMesotheliomaRenal Cancer+3 more
Nuvectis Pharma, Inc.140 enrolled12 locationsNCT05873686
Recruiting
Phase 1
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc.18 enrolled3 locationsNCT07315113